☆ 4.7 Editorial Material

Stenotrophomonas maltophilia Susceptibility Testing Challenges and Strategies

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Related references

Note: Only part of the references are listed.

Article Microbiology

In Vitro Activity and In Vivo Efficacy of Cefiderocol against Stenotrophomonas maltophilia

Rio Nakamura et al.

Summary: Cefiderocol is a novel antibiotic that shows potent activity against difficult-to-treat Gram-negative bacteria, including strains resistant to carbapenems. In in vitro and animal studies, Cefiderocol demonstrated strong antimicrobial activity against Stenotrophomonas maltophilia, even against strains resistant to trimethoprim-sulfamethoxazole. These results suggest that Cefiderocol could be a promising treatment option for infections caused by S. maltophilia, especially those resistant to traditional antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Evaluation of the Performance of Manual Antimicrobial Susceptibility Testing Methods and Disk Breakpoints for Stenotrophomonas maltophilia

Ayesha Khan et al.

Summary: Stenotrophomonas maltophilia is a challenging pathogen with intrinsic resistance to many antibiotics, except trimethoprim-sulfamethoxazole. Alternative therapies such as levofloxacin, minocycline, and ceftazidime are used for neutropenic patients, but testing for susceptibility is necessary. Disk and gradient diffusion tests show good performance for S. maltophilia, except for levofloxacin and ceftazidime. Further studies are needed to establish interpretive criteria for certain antibiotics.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)

Add to Collection

Article Microbiology

Evaluation of the Vitek 2, Phoenix, and MicroScan for Antimicrobial Susceptibility Testing of Stenotrophomonas maltophilia

Ayesha Khan et al.

Summary: This study evaluated the performance of different systems in detecting drug resistance of Stenotrophomonas maltophilia and found inconsistencies in the agreement among different systems under different drugs and corresponding CLSI breakpoints, with the presence of significant errors.

JOURNAL OF CLINICAL MICROBIOLOGY (2021)

Add to Collection

Article Microbiology

Activity of Potential Alternative Treatment Agents for Stenotrophomonas maltophilia Isolates Nonsusceptible to Levofloxacin and/or Trimethoprim-Sulfamethoxazole

M. Biagi et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2020)

Add to Collection

Article Immunology

Monitoring Ceftazidime-Avibactam and Aztreonam Concentrations in the Treatment of a Bloodstream Infection Caused by a Multidrug-Resistant Enterobacter sp. Carrying Both Klebsiella pneumoniae Carbapenemase-4 and New Delhi Metallo-β-Lactamase-1

Mohamad Yasmin et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints

Michael J. Satlin et al.

CLINICAL INFECTIOUS DISEASES (2020)

Add to Collection

Article Immunology

Antimicrobial Susceptibility of Acinetobacter calcoaceticus-Acinetobacter baumannii Complex and Stenotrophomonas maltophilia Clinical Isolates: Results From the SENTRY Antimicrobial Surveillance Program (1997-2016)

Ana C. Gales et al.

OPEN FORUM INFECTIOUS DISEASES (2019)

Add to Collection

Article Infectious Diseases

Efficacy of combination therapy versus monotherapy in the treatment of Stenotrophomonas maltophilia pneumonia

Megan D. Shah et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)

Add to Collection

Article Microbiology

Comparative In Vivo Antibacterial Activity of Human-Simulated Exposures of Cefiderocol and Ceftazidime against Stenotrophomonas maltophilia in the Murine Thigh Model

Iris H. Chen et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)

Add to Collection

Review Infectious Diseases

Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis

J-H. Ko et al.

CLINICAL MICROBIOLOGY AND INFECTION (2019)

Add to Collection

Review Microbiology

Antimicrobial Susceptibility Testing for Polymyxins: Challenges, Issues, and Recommendations

Fereshteh Ezadi et al.

JOURNAL OF CLINICAL MICROBIOLOGY (2019)

Add to Collection

Article Critical Care Medicine

Outcomes of Stenotrophomonas maltophilia hospital-acquired pneumonia in intensive care unit: a nationwide retrospective study

Philippe Guerci et al.

CRITICAL CARE (2019)

Add to Collection

Article Infectious Diseases

Antimicrobial susceptibility testing of colistin - evaluation of seven commercial MIC products against standard broth microdilution for Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter spp.

E. Matuschek et al.

CLINICAL MICROBIOLOGY AND INFECTION (2018)

Add to Collection

Article Biochemistry & Molecular Biology

Structural/mechanistic insights into the efficacy of nonclassical β-lactamase inhibitors against extensively drug resistant Stenotrophomonas maltophilia clinical isolates

Karina Calvopina et al.

MOLECULAR MICROBIOLOGY (2017)

Add to Collection

Article Microbiology

Avibactam Restores the Susceptibility of Clinical Isolates of Stenotrophomonas maltophilia to Aztreonam

Maria F. Mojica et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)

Add to Collection

Review Microbiology

Polymyxins: Antibacterial Activity, Susceptibility Testing, and Resistance Mechanisms Encoded by Plasmids or Chromosomes

Laurent Poirel et al.

CLINICAL MICROBIOLOGY REVIEWS (2017)

Add to Collection

Article Microbiology

The Efflux Pump SmeDEF Contributes to Trimethoprim-Sulfamethoxazole Resistance in Stenotrophomonas maltophilia

Maria Blanca Sanchez et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)

Add to Collection

Article Infectious Diseases

Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly?

David M. Livermore et al.

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2012)

Add to Collection

Article Microbiology

Induction of L1 and L2 β-lactamase production in Stenotrophomonas maltophilia is dependent on an AmpR-type regulator

Aki Okazaki et al.

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)

Add to Collection

Review Infectious Diseases

Antimicrobial therapy for Stenotrophomonas maltophilia infections

A. C. Nicodemo et al.

EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2007)

Add to Collection

© Peeref 2019-2024. All rights reserved.